The Anatomy Of Astellas And Poseida's CAR-T Deal

 
• By David Wild

Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.

Behind the Deal

More from Leadership

More from Growth